Semaglutide

Semaglutide may influence impulse control in some patients, affecting spending behaviors. Here’s the mechanism, what research shows, and what to watch for.

Semaglutide shows potential in reducing alcohol cravings through GLP-1 receptor mechanisms. Research data, clinical evidence, and what patients should

Semaglutide can worsen social anxiety in 15–20% of patients through nausea-triggered isolation, though symptom management and metabolic improvements often

Semaglutide microdosing carries risks most guides ignore: receptor desensitisation, dose inconsistency, and loss of therapeutic efficacy. Here’s what

Semaglutide microdosing starts at 0.25–0.5mg weekly, titrating slowly to minimize side effects while achieving sustained weight loss through optimized

Semaglutide shows metabolic benefits that may slow aging markers — but it’s not a longevity drug. Here’s what the evidence actually supports.

Semaglutide reduces cardiovascular mortality by 20% and slows biological aging markers, but lifespan extension requires sustained metabolic correction

Semaglutide shows neuroprotective effects through GLP-1 receptor activation in the brain, reducing inflammation and potentially improving cognitive

Semaglutide doesn’t treat addiction, but may reduce cravings in recovery by modulating dopamine pathways. Here’s what the research shows and doesn’t.